E195 Bishal Gyawali and the Quest for Common Sense Oncology

This week's guest is Dr. Bishal Gyawali. Bishal is an oncologist at Queen's University and a policy researcher. His focus as a researcher has been both sensational and at the same time extremely fundamental. Bishal has been asking questions around how we decide which drugs are approved for funding by the government, as well as how we might best allocate resources to help cancer patients around the world. Bishal has been an integral part of the "Common Sense Oncology" movement, which will promote interventions that measurably improve the lives of patients, promoting effective treatments but  also challenging interventions that might cause more harm than good.Our conversation focused around Bishal's training, how he became interested in cancer health policy and his thoughts around the idea of value in cancer care. We also discussed Bishal's thoughtful use of technology, blogs, and social media. Links:Grounded in Groundshot Podcast – Dr. Bishal Gyawali BG lab: Dr. Bishal Gyawali Common Sense Oncology: Home - Common Sense Oncology Mittal A, Kim MS, Dunn S, Wright K, Gyawali B. Frequently asked questions on surrogate endpoints in oncology-opportunities, pitfalls, and the way forward. EClinicalMedicine. 2024 Sep 13;76:102824. doi: 10.1016/j.eclinm.2024.102824. PMID: 39764569; PMCID: PMC11701476.Surrogate Endpoints: The 15 Most Common Misunderstandings in Oncology Cancer groundshot: Access to proven treatments must parallel development of new therapies Do Oncology Board Exams Make Us Better Doctors? Ending Medical Reversal: Ending Medical Reversal | Hopkins Press